This blog post from Cure-Hub LLC is not a peer-reviewed primary source, but the claims made within do cite the literature fairly appropriately and accurately.

Here I've outlined the most important claims, and where citations were provided, I included excerpts from the cited literature to support the claim.

> "multiple studies show that reinfection in people with natural immunity is rare"

- "A previous history of SARS-CoV-2 infection was associated with an 84% lower risk of infection, with median protective effect observed 7 months following primary infection. This study shows that previous infection with SARS-CoV-2 induces effective immunity to future infections in most individuals." [1]

- "Reinfection is rare in the young and international population of Qatar. Natural infection appears to elicit strong protection against reinfection with an efficacy ~95% for at least seven months." [2]

- "To our knowledge, this is the first systematic review to synthesise the evidence on the risk of SARS‐CoV‐2 reinfection over time. [...] Reinfection was an uncommon event (absolute rate 0%–1.1%), with no study reporting an increase in the risk of reinfection over time. [...] These data suggest that naturally acquired SARS‐CoV‐2 immunity does not wane for at least 10 months post‐infection. However, the applicability of these studies to new variants or to vaccine‐induced immunity remains uncertain." [3]

- "Cumulative incidence of COVID-19 was examined among 52238 employees in an American healthcare system. COVID-19 did not occur in anyone over the five months of the study among 2579 individuals previously infected with COVID-19, including 1359 who did not take the vaccine. [...] Individuals who have had SARS-CoV-2 infection are unlikely to benefit from COVID-19 vaccination, and vaccines can be safely prioritized to those who have not been infected before." [4]

> "Data also suggests that natural immunity is more protective than vaccine related immunity"

> "The most significant difference between vaccinated and naturally infected individuals is the antibody response against nucleocapsid (N) protein"

The author is basing this claim on the Cure-Hub data, but did not cite any literature on this. The finding is consistent with other papers, for example see [5].

- "The nucleocapsid protein (NP) is an immunodominant antigen for which the antibody response increases in concordance with natural exposure (Figure 2A,3A and 4)." [5]

- "However, nucleocapsid is not a component of the mRNA vaccines and consequently there is no vaccine-induced increase in Ab against this antigen. Accordingly, anti-spike antibody levels increased in vaccinees while the nucleocapsid protein Ab level remained constant." [5]

> "Cure-Hub's data shows less antibody diversity in vaccinated individuals than naturally infected individuals."

> "Fewer unique antibodies provide the virus with an avenue for immune escape through S protein mutations."

The author did not cite any literature on this claim either, so I'm providing an example here [6].

- "The spike protein receptor-binding domain (RBD) of SARS-CoV-2 is the molecular target for many vaccines and antibody-based prophylactics aimed at bringing COVID-19 under control." [6]

- "Such a narrow molecular focus raises the specter of viral immune evasion as a potential failure mode for these biomedical interventions. With the emergence of new strains of SARS-CoV-2 with altered transmissibility and immune evasion potential, a critical question is this: how easily can the virus escape neutralizing antibodies (nAbs) targeting the spike RBD?" [6]

- "Our modeling suggests that SARS-CoV-2 mutants with one or two mildly deleterious mutations are expected to exist in high numbers due to neutral genetic variation, and consequently resistance to vaccines or other prophylactics that rely on one or two antibodies for protection can develop quickly -and repeatedly- under positive selection." [6]

- "The speed at which nAb resistance develops in the population increases substantially as the number of infected individuals increases, suggesting that complementary strategies to prevent SARS-CoV-2 transmission that exert specific pressure on other proteins (e.g., antiviral prophylactics) or that do not exert a specific selective pressure on the virus (e.g., high-efficiency air filtration, masking, ultraviolet air purification) are key to reducing the risk of immune escape" [6]

- "Strategies for viral elimination should therefore be diversified across molecular targets and therapeutic modalities" [6]

[1] SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040523/

[2] SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5...

[3] Quantifying the risk of SARS‐CoV‐2 reinfection over time
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209951/

[4] Necessity of COVID-19 vaccination in previously infected individuals
https://www.medrxiv.org/content/10.1101/2021.06.01.21258176v...

[5] Distinct SARS-CoV-2 Antibody Responses Elicited by Natural Infection and mRNA Vaccination
https://www.biorxiv.org/content/10.1101/2021.04.15.440089v4

[6] Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein
https://pubmed.ncbi.nlm.nih.gov/33909660/